Clinical Trial Update: Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating sorafenib in combination with thalidomide for hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (sorafenib) (sorafenib)
• Thalomid (thalidomide)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: TERMINATED